imvotamab
IGM-2323-001
Phase 2 small_molecule terminated
Quick answer
imvotamab for Non-Hodgkin Lymphoma is a Phase 2 program (small_molecule) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ADC Therapeutics SA
- Indication
- Non-Hodgkin Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated